Doxorubicin
- Generic Name
- Doxorubicin
- Brand Names
- Adriamycin, Doxil, Myocet, Caelyx pegylated liposomal, Zolsketil pegylated liposomal, Myocet liposomal (previously Myocet), Celdoxome pegylated liposomal
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 23214-92-8
- Unique Ingredient Identifier
- 80168379AG
- Background
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970. Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its deta...
- Indication
Doxorubicin is indicated for the treatment of neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin and non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue and bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinom...
- Associated Conditions
- AIDS-related Kaposi's Sarcoma, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Advanced Endometrial Cancer, Advanced Ovarian Cancer, Breast Cancer, Hodgkin's Lymphoma, Metastatic Bone Sarcomas, Metastatic Breast Cancer, Metastatic Soft Tissue Sarcoma, Metastatic Thyroid Cancer, Metastatic Urothelial Cancer, Multiple Myeloma (MM), Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Sezary Syndrome, Waldenström's Macroglobulinemia (WM), Advanced Thymoma, Advanced uterine sarcoma, Metastatic Bronchogenic Carcinoma, Metastatic Gastric carcinoma, Metastatic Neuroblastoma, Metastatic Ovarian carcinoma, Metastatic Wilms' tumor
- Associated Therapies
- -
Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment
- Conditions
- Interventions
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Children's Cancer Group, China
- Target Recruit Count
- 96
- Registration Number
- NCT06563245
First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- The National Center of Oncology, Azerbaijan
- Target Recruit Count
- 200
- Registration Number
- NCT06531447
- Locations
- 🇦🇿
Elchin Mansurov, Baku, Azerbaijan
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT06528496
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour
- Conditions
- Interventions
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 198
- Registration Number
- NCT06524583
- Locations
- 🇫🇷
Centre Georges Francois Leclerc, Dijon, France
🇫🇷Institut Paoli Calmettes, Marseille, France
🇫🇷Centre Francois Baclesse, Caen, France
A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-07-24
- Target Recruit Count
- 528
- Registration Number
- NCT06516978
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy
- Conditions
- Interventions
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 520
- Registration Number
- NCT06486441
- Locations
- 🇯🇵
Mie University Hospital, Mie, Japan
🇯🇵Hyogo Cancer Center, Hyogo, Japan
🇺🇸City of Hope, Irvine, California, United States
Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-06-25
- Last Posted Date
- 2024-06-25
- Target Recruit Count
- 30
- Registration Number
- NCT06474481
Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2024-06-21
- Target Recruit Count
- 20
- Registration Number
- NCT06468943
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Nanjing, China
Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
- Conditions
- Interventions
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 152
- Registration Number
- NCT06441097
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 90
- Registration Number
- NCT06425302
- Locations
- 🇺🇸
Local Institution - 0020, New Brunswick, New Jersey, United States
🇩🇪Gemeinschaftspraxis Hämatologie - Onkologie Freiberg-Richter, Jacobasch, Illmer, Wolf, Dresden, Germany
🇮🇹Local Institution - 0179, Rozzano, Milano, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.